Advanced search
Publication Cover
Modern Rheumatology Volume 18, 2008 - Issue 4
Journal homepage
16
Views
39
CrossRef citations to date
0
Altmetric
Original Article

Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet’s disease before ocular attack: a possible predictive marker of ocular attack

Yuki NankeInstitute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, JapanCorrespondence[email protected]
,
Shigeru KotakeInstitute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan
,
Mari GotoDepartment of Ophthalmology, Medical Center East, Tokyo Women’s Medical University, Tokyo, Japan
,
Hiroshi UjiharaDepartment of Ophthalmology, Medical Center East, Tokyo Women’s Medical University, Tokyo, Japan
,
Masao MatsubaraDepartment of Ophthalmology, Medical Center East, Tokyo Women’s Medical University, Tokyo, Japan
&
Naoyuki KamataniInstitute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan
Pages 354-358 | Received 29 Nov 2007, Accepted 15 Feb 2008, Published online: 02 Jan 2014

References

  • Sakane T. Behcet's disease. N Eng J Med. 1999;341:1284–91.
  • Nanke Y, Kotake S, Tateishi M, Yamanaka H, Kamatani N. Synovial histology in three Behcet's disease patients with orthopedic surgery. Clin Exp Rheumatol. 2002;20:35–44.
  • Nanke Y, Kotake S, Ogasawara K et al. Raised plasma adreno-medullin level in Behcet's disease patients. Mod Rheumatol. 2003;13:139–42.
  • Sakaguchi S, Sakaguchi N, Shimizu J. Immunological tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and trans-plantation tolerance. Immunol Rev. 2001;182: 18–32.
  • Kukreja A, Cost G, Marker J et al. Multiple immuno-regulatory defects in type-1 diabetes J. Clin Investig. 2002;109:131–40.
  • Amelsfort J, Jacvobs K, Bijlsma J, Lafeber F, Taams L. CD4+ CD25+ regulatory T cells in rheumatoid arthritis. Differ-ence in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004;50: 2775–85.
  • Cao D. Isolation and functional characterization of regulatory CD25brightCD4 T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003;33:215–23.
  • Crispin JC, Martinez A, Varela JA. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoim-mun. 2003;21:273–6.
  • Gottenberg JE, Lavie F, Abbed K et al. CD4+ CD25+ high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. J Autoimmun. 2005;24:235–42.
  • International Study Group for Behcet's Disease: criteria for diagnosis of Behcet's disease. Lancet. 1999;335:1078–80.
  • Behcet's Disease Research Committee of Japan. Behcet's dis-ease: a guide to diagnosis of Behcet's disease. Jpn J Ophthalmol. 1974;18: 291–4.
  • Jiao Z, Wang W, Jia R et al. Accumulation of FoxP3-expressing CD4(+)CD25(+) T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol. 2007;36:428–33.
  • Grajewski R, Silver P, Agarwal RK et al. Endogenous IRBP can be dispensable for generation of natural CD4+ CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. JEM. 2006;203:851–6.
  • Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in Rheumatoid arthritis and reversal by anti-TNFa therapy. J Exp Med. 2004;200:277–85.
  • Sarin A, Conan-Cibotti M, Henkart P. Cytotoxic effect of TNF and lymphotoxin on T lymphoblasts. J Immunol. 1995;155:3716–8.
  • Hon S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Fox P3. Science. 2003;299: 1057–61.
  • Allan SE, Crome SQ, Crelfin NK et al. Activation-induced FoxP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007;19:345–54.
  • Hamzaoui K, Hamzaoui A, Houman H. CD4+ CD25+regulatory T cells in patients with Behcet's disease. Clin Exp Rheumatol. 2006;24: 571–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.